Zeo ScientifiX's Total Assets for the quarter that ended in Apr. 2026 was $3.89 Mil.
During the past 12 months, Zeo ScientifiX's average Total Assets Growth Rate was 128.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -18.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 0.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 39.00% per year.
During the past 13 years, Zeo ScientifiX's highest 3-Year average Total Assets Growth Rate was 212.90%. The lowest was -18.90%. And the median was 35.15%.
Note:
The Net Income data used here is four times the quarterly (Apr. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Zeo ScientifiX's Asset Turnover for the quarter that ended in Apr. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Zeo ScientifiX Total Assets Related Terms
Zeo ScientifiX Total Assets Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Zeo ScientifiX's Total Assets for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (ZEOX) has a Total Assets of $3.89 Mil as of Apr. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Zeo ScientifiX and its competitors.
Is Zeo ScientifiX's Total Assets too high?
Zeo ScientifiX's current Total Assets is $3.89 Mil. Overall, Zeo ScientifiX has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Total Assets compare to JUNS and HOOK?
Zeo ScientifiX's Total Assets of $3.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Zeo ScientifiX and its competitors. Zeo ScientifiX's current Total Assets is $3.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.67, compared to a current price of $1.90 — trading 28.8% below its estimated fair value. The current Total Assets is $3.89 Mil. Zeo ScientifiX's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Total Assets is $3.89 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.90 is trading 28.8% below its estimated GF Value™ of $2.67.
GuruFocus considers Zeo ScientifiX to be Modestly Undervalued.
Key valuation signals for ZEOX:
Total Assets: $3.89 Mil
GF Value™: $2.67 vs. price of $1.90 (28.8% below fair value)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
56GF Score
Get the complete analysis for ZEOX
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
